Financials data is unavailable for this security.
View more
Year on year RTW Biotech Opportunities Ltd had net income fall -58.91% from 83.19m to 34.18m despite a 96.37% increase in revenues from 4.17m to 8.19m.
| Gross margin | 45.96% |
|---|---|
| Net profit margin | -263.16% |
| Operating margin | 42.47% |
| Return on assets | -11.97% |
|---|---|
| Return on equity | -14.55% |
| Return on investment | -14.39% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at RTW Biotech Opportunities Ltd fell by 27.26m. Cash Flow from Financing totalled 97.08m or 1,185.37% of revenues. In addition the company used 124.34m for operations while cash used for investing totalled .
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.77 |
|---|---|
| Tangible book value per share | 1.77 |
More ▼
Balance sheet in USDView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.2158 |
|---|---|
| Total debt/total capital | 0.1775 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -74.22%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -15.74 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -155.63 |
